Key result
Adding 24-hour urinary aldosterone to plasma screening improves primary aldosteronism detection, reaching ~89% sensitivity.
Why the study?
Plasma-based screening for primary aldosteronism is influenced by short-term physiologic variation and medications, and non-salt-loaded 24-h urine collection may complement plasma screening.
Does integrating non-salt-loaded 24-h urinary aldosterone and tetrahydroaldosterone with plasma screening improve diagnostic accuracy for primary aldosteronism compared to plasma-based screening alone in patients evaluated for primary aldosteronism?
Observational (n=1,316)
Yes
Does integrating non-salt-loaded 24-h urinary aldosterone and tetrahydroaldosterone with plasma screening improve diagnostic accuracy for primary aldosteronism compared to plasma-based screening alone in patients evaluated for primary aldosteronism?
Integrating non-salt-loaded 24-h urinary aldosterone and tetrahydroaldosterone measured by LC-MS/MS with plasma biomarkers significantly improves screening sensitivity for primary aldosteronism compared to standard guideline-based plasma screening.
Answers are grounded in this paper and cite their sources.
Combined urine-plasma panel may improve primary aldosteronism screening sensitivity; leaves open prospective validation before clinical adoption.
Plasma-based screening for primary aldosteronism (PA), namely aldosterone-to-renin ratio, plasma aldosterone concentration (PAC), and plasma renin activity (PRA), is influenced by short-term physiologic variation and medications. Non-salt-loaded 24-h urine collection may complement plasma screening. In this multicenter retrospective observational study (October 2013-September 2020), non-salt-loaded 24-h urinary aldosterone (UALD) and tetrahydroaldosterone (UTHA) were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in patients evaluated for PA. A chronological derivation (2013-2015) and validation (2015-2020) design was used. Optimal cutoffs for UALD, UTHA, and their sum (SUM) were derived using ROC analysis with bootstrapping. In patients with paired urine and plasma measurements, logistic models were developed for a urine panel (UALD, UTHA), a plasma panel (PAC, PRA), and a combined panel. A points-based Combined Urine-Plasma Score (CUPS) was constructed for clinical implementation. Among 1316 eligible cases, derived cutoffs were UALD >39 nmol/day, UTHA >179 nmol/day, and SUM >190 nmol/day, all with AUCs of 0.84-0.85. In 1076 cases, AUCs were 0.85 for the urine panel, 0.89 for the plasma panel, and 0.93 for the combined panel. The combined panel achieved 89% sensitivity and 84% specificity (positive predictive value 59%, negative predictive value (NPV) 97%), improving sensitivity compared with Endocrine Society rule-based screening (66%) but with similar specificity (89%). CUPS showed comparable performance (sensitivity 85%, specificity 86%, NPV 96%). Non-salt-loaded 24-h urinary aldosterone biomarkers measured by LC-MS/MS provide robust screening performance and add incremental value to plasma-based screening. Integrating urine and plasma markers (including CUPS) may improve PA detection in routine practice.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) conducted an observational in Primary aldosteronism (n=1,316). Combined urine (24-h urinary aldosterone and tetrahydroaldosterone) and plasma (PAC, PRA) screening panel vs. Plasma panel alone or Endocrine Society rule-based screening was evaluated on Diagnostic performance (sensitivity, specificity, and AUC) for detecting primary aldosteronism (AUC 0.93). Combining 24-h urinary aldosterone biomarkers with plasma screening achieved an AUC of 0.93 and improved sensitivity for primary aldosteronism vs rule-based screening.
Synapse has enriched 10 related papers. Consider them for comparative context: